Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Pediatrics

Pediatrics

                        FDA Perspectives on Pediatric Health
          Pediatric Medical Product Safety
          Pediatric Ethics
          International Collaboration / Pediatric Cluster
          Pediatric Science and Research Activities
          Medical Products for Newborns
          Pediatric Labeling Changes
          Reports, Statistics, Reviews and Databases Home
          Science & Research
          Science and Research Special Topics
          Pediatrics
          Medical Products for NewbornsPediatrics Medical Products for Newborns
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe first several weeks of life is a time of critical growth and development for babies. Newborns undergo rapid changes in all their organ systems and tissues, making them a uniquely vulnerable population. Medical products approved by the FDA for newborn babies must be proven to be safe and effective.

Medical products need to be studied in neonatal clinical trials. The growth and developmental changes that occur during the newborn period (the first 28 days of life for full-term babies) can affect the safety, effectiveness and dosing of medicines when used in newborns. Medical devices for newborns need to be designed taking into consideration a newborn’s size, growth, activity and physiologic changes. Newborns’ responses to medical products often can’t be predicted from data collected in studies of adults.

Long-term safety studies are often important to assess the safety of medical products used in newborns because important health effects resulting from medical products used during the newborn period may not become apparent until after a baby has grown older.

Federal laws incentivize and require pediatric studies under certain circumstances but there are still many challenges for addressing the needs of newborns. For example, most drugs used in neonatal intensive care units have not been approved by the FDA for use in newborns. Doctors routinely treat newborns with medicines approved for adults or older children if the doctor believes the medicine is the best available treatment option for the newborn. Additionally, many medical conditions that occur in newborns don’t occur in older children or adults, so data from pediatric or adult studies often are not available to help inform the assessment of safety and effectiveness of medical products for these conditions.

Labeling changes for medical products for children and newborns

Advancing treatments for newborns and including evidence-based information in product labeling about how to safely treat newborns continues to be a key area of focus for the FDA. For example, the agency:

Supports medical product development by providing neonatal-perinatal medicine expertise across the agency
	Explores neonatology considerations raised by pediatric studies required or requested under federal laws including the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act
	Trains staff across the agency and provides expertise to external stakeholders on issues in neonatal medical product development
	Advances regulatory science for clinical trials involving neonates to support the agency’s decision-makingLabeling Changes for Neonates 1999 – 2022

The table below includes labeling changes for pediatric and neonatal drugs under certain federal laws. Drugs may be labeled with information for neonates even if studies were not conducted in neonates. For example, drugs may be labeled with safety information based on non-clinical data.

Graph 02062023
International Neonatal Consortium

The FDA participates in the International Neonatal Consortium (INC), a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of medical products for neonates. The consortium has spearheaded many opportunities to improve and accelerate neonatal product development. For example, the INC developed a neonatal adverse event severity scale to help improve the quality of safety evaluations in neonatal clinical trials.

Additional resources

Draft guidance: Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development 

	Guidance snapshot and podcast (podcast transcript)
	Final guidance: General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products
	Guidance snapshot and podcast (podcast transcript)
	Draft guidance: General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products
	Draft guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials

                                                                                  Content current as of:
      02/10/2023Pediatrics

          
                        FDA Perspectives on Pediatric Health
          Pediatric Medical Product Safety
          Pediatric Ethics
          International Collaboration / Pediatric Cluster
          Pediatric Science and Research Activities
          Medical Products for Newborns
          Pediatric Labeling Changes
          Reports, Statistics, Reviews and Databases
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop